Validation of the CLIF-C OF Score and CLIF-C ACLF Score to Predict Transplant-Free Survival in Patients with Liver Cirrhosis and Concomitant Need for Intensive Care Unit Treatment.


Journal

Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208

Informations de publication

Date de publication:
29 Apr 2023
Historique:
received: 14 03 2023
revised: 07 04 2023
accepted: 27 04 2023
medline: 29 5 2023
pubmed: 27 5 2023
entrez: 27 5 2023
Statut: epublish

Résumé

Both the Chronic Liver Failure Consortium (CLIF-C) organ failure score (OFs) and the CLIF-C acute-on-chronic-liver failure (ACLF) score (ACLFs) were developed for risk stratification and to predict mortality in patients with liver cirrhosis and ACLF. However, studies validating the predictive ability of both scores in patients with liver cirrhosis and concomitant need for intensive care unit (ICU) treatment are scarce. The aim of the present study is to validate the predictive ability of the CLIF-C OFs and CLIF-C ACLFs regarding the rationale of ongoing ICU treatment and to investigate their predictive ability regarding 28-days (short-), 90-days (medium-), and 365-days (long-term) mortality in patients with liver cirrhosis treated in an ICU. Patients with liver cirrhosis and acute decompensation (AD) or ACLF and concomitant need for ICU treatment were retrospectively analyzed. Predictive factors for mortality, defined as transplant-free survival, were identified using multivariable regression analyses and the predictive ability of CLIF-C OFs, CLIF-C ACLFs, MELD score, and AD score (ADs) was assessed by determining the AUROC. Of 136 included patients, 19 patients presented with AD and 117 patients with ACLF at ICU admission. In multivariable regression analyses, CLIF-C OFs as well as CLIF-C ACLFs were independently associated with higher short-, medium-, and long-term mortality after adjusting for confounding variables. The predictive ability of the CLIF-C OFs in the total cohort in short-term was 0.687 (95% CI 0.599-0.774). In the subgroup of patients with ACLF, the respective AUROCs were 0.652 (95% CI 0.554-0.750) and 0.717 (95% CI 0.626-0.809) for the CLIF-C OFs and for the CLIF-C ACLFs, respectively. ADs performed well in the subgroup of patients without ACLF at ICU admission with an AUROC of 0.792 (95% CI 0.560-1.000). In the long-term, the AUROCs were 0.689 (95% Cl 0.581-0.796) and 0.675 (95% Cl 0.550-0.800) for CLIF-C OFs and CLIF-C ACLFs, respectively. The predictive ability of CLIF-C OFs and CLIF-C ACLFs was relatively low to predict short- and long-term mortality in patients with ACLF with concomitant need for ICU treatment. However, the CLIF-C ACLFs may have special merit in judging futility of further ICU treatment.

Identifiants

pubmed: 37241098
pii: medicina59050866
doi: 10.3390/medicina59050866
pmc: PMC10221777
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Liver Transpl. 2001 Jul;7(7):567-80
pubmed: 11460223
J Hepatol. 2021 Jul;75 Suppl 1:S49-S66
pubmed: 34039492
Crit Care. 2018 Oct 10;22(1):254
pubmed: 30305132
Hepatology. 2017 Jul;66(1):292-294
pubmed: 28195348
J Hepatol. 2021 Dec;75(6):1346-1354
pubmed: 34364917
J Hepatol. 2015 Apr;62(1 Suppl):S131-43
pubmed: 25920082
Can J Gastroenterol Hepatol. 2021 Sep 24;2021:9953106
pubmed: 34608435
Gastroenterology. 2013 Jun;144(7):1426-37, 1437.e1-9
pubmed: 23474284
Semin Liver Dis. 2016 May;36(2):117-22
pubmed: 27172352
Ann Intensive Care. 2017 Dec;7(1):33
pubmed: 28321803
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
J Hepatol. 2010 Sep;53(3):397-417
pubmed: 20633946
J Hepatol. 2014 Nov;61(5):1038-47
pubmed: 24950482
JHEP Rep. 2021 Aug 27;3(6):100355
pubmed: 34805815
Hepatology. 2021 Apr;73(4):1478-1493
pubmed: 32706906
PLoS One. 2022 Nov 22;17(11):e0277959
pubmed: 36413538
Transpl Int. 2022 Mar 17;35:10108
pubmed: 35572467
Ann Intensive Care. 2016 Dec;6(1):94
pubmed: 27709556
PLoS One. 2021 Apr 1;16(4):e0249342
pubmed: 33793644

Auteurs

Michael Nagel (M)

Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany.
Cirrhosis Center Mainz (CCM), University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany.
Department of Gastroenterology, Hematology, Oncology and Endocrinology, Klinikum Dortmund, 44137 Dortmund, Germany.

Ruben Westphal (R)

Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany.

Max Hilscher (M)

Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany.
Cirrhosis Center Mainz (CCM), University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany.
Department of Gastroenterology, Hematology, Oncology and Endocrinology, Klinikum Dortmund, 44137 Dortmund, Germany.

Peter R Galle (PR)

Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany.
Cirrhosis Center Mainz (CCM), University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany.

Jörn M Schattenberg (JM)

Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany.
Cirrhosis Center Mainz (CCM), University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany.

Oliver Schreiner (O)

Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany.
Cirrhosis Center Mainz (CCM), University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany.

Christian Labenz (C)

Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany.
Cirrhosis Center Mainz (CCM), University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany.

Marcus Alexander Wörns (MA)

Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany.
Cirrhosis Center Mainz (CCM), University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany.
Department of Gastroenterology, Hematology, Oncology and Endocrinology, Klinikum Dortmund, 44137 Dortmund, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH